NCT03132454 2026-04-15
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
28 trialsNCT05397496 2026-03-17
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Phase 1 Active not recruiting
NCT00586391 2026-02-06
CRETI-NH
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05044039 2026-02-02
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
Phase 1 Active not recruiting
NCT02146924 2025-12-05
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02091245 2025-12-02
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03740334 2025-11-21
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04684563 2025-11-10
huCART19-IL18 in CD19+ Cancers
University of Pennsylvania
Phase 1 Active not recruiting
NCT03620058 2025-10-14
CART22 Alone or in Combination With huCART19 for ALL
University of Pennsylvania
Phase 1 Active not recruiting
NCT01815749 2025-10-06
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04606433 2025-09-26
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05993949 2025-09-23
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Active not recruiting
NCT02159495 2025-09-16
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
City of Hope Medical Center
Phase 1 Active not recruiting
NCT00710892 2025-07-11
CASPALLO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT00840853 2025-07-09
MULTIPRAT
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05139004 2025-07-08
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04732845 2025-07-03
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02494882 2025-07-02
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03774654 2025-07-01
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03241940 2025-06-29
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Active not recruiting
NCT01683279 2025-06-17
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03186118 2025-06-17
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT01430390 2025-06-11
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT01044069 2025-05-23
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04013685 2025-05-02
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Phase 1 Active not recruiting
NCT00641381 2025-05-01
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04088864 2025-03-30
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Phase 1 Active not recruiting